Global Acquired Hemophilia Therapeutics Market: Overview
Acquired hemophilia is a rare autoimmune disease, wherein body’s own immune system destroys blood clotting factor and prevents blood clotting, resulting in excessive bleeding. This is not congenital and develops suddenly due to abnormality in the immune system. Acquired hemophilia is characterized by production of antibodies, also called inhibitors, which attack clotting factor VIII, a protein required for normal blood clotting, leading to uncontrolled bleeding. Symptoms of acquired hemophilia include prolonged bleeding, hematuria, gastrointestinal bleeding, bruising, and frequent nosebleeds. The causes of acquired hemophilia include autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and psoriasis. It is also associated with certain medical conditions such as lymphoproliferative diseases, cancer, tumors, and pregnancy. Acquired hemophilia is extremely rare and can be fatal. It can be diagnosed by physical examination describing the bleeding patterns. X-ray or MRI scan can be done to detect internal bleeding. Screening coagulation laboratory tests and factor VIII test are preferred to confirm acquired hemophilia.
Global Acquired Hemophilia Therapeutics Market: Key Trends
Rise in prevalence of autoimmune diseases, increase in the geriatric population, surge in research expenditure in developing countries, high unmet clinical needs in patients with acquired hemophilia, rise in awareness about the condition, and favorable reimbursement policies are the major factors projected to drive the global acquired hemophilia therapeutics market during the forecast period. However, limited availability of novel treatments for acquired hemophilia in developing countries acts as a major restraint of the global acquired hemophilia therapeutics market.
Global Acquired Hemophilia Therapeutics Market: Segmentation
The global acquired hemophilia therapeutics market can be segmented based on type, distribution channel, and region. In terms of type, the market can be bifurcated into traditional therapies and advanced therapies. The traditional therapies segment can be categorized into steroid treatment, cytotoxic treatment, and immunomodulatory treatment. The advanced therapies segment can be classified into desmopressin, recombinant activated factor VII, recombinant activated factor VIII, and activated prothrombin complex concentrate (aPCC). The advanced therapies segment dominated the market in 2017 and is expected to sustain its position during the forecast period. This is attributed to effectiveness of novel therapies in the treatment of acquired hemophilia. Based on distribution channel, the global acquired hemophilia therapeutics market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2017 due to high preference for this channel of distribution. The segment is projected to sustain its leadership position from 2018 to 2026.
Global Acquired Hemophilia Therapeutics Market: Regional Analysis
In terms of region, the global acquired hemophilia therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for major share of the global market during the forecast period. Increase in the geriatric population, high awareness about the disease condition, favorable government support, and improved health care infrastructure are the major factors anticipated to propel the market in North America from 2018 to 2026. According to National Organization for Rare Disorders (NORD) estimates, acquired hemophilia will affect approximately 0.2 to 1 individuals per 1,000,000/year in the U.S. The acquired hemophilia therapeutics market in Asia Pacific is expected to expand at a high CAGR between 2018 and 2026. This high growth rate can be attributed to increase in research expenditure and rise in awareness about the disease among the population.
Global Acquired Hemophilia Therapeutics Market: Competitive Landscape
Key players operating in the global acquired hemophilia therapeutics are Biogen, Inc., Shire plc, Baxter, Novo Nordisk A/S, Genentech, Inc., Ferring B.V., and Pfizer, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.